Literature DB >> 36083426

Roles and outcomes of stereotactic biopsy for adult patients with brainstem lesion.

Henri Malaizé1, Florence Laigle-Donadey2, Maximilien Riche1, Pauline Marijon1, Karima Mokhtari3,4, Franck Bielle3,4, Suzanne Tran3,4, Lucia Nichelli3, Kevin Beccaria5, Ahmed Idbaih2, Khê Hoang-Xuan2, Mehdi Touat2, Alexandre Carpentier1, Bertrand Mathon6,7.   

Abstract

PURPOSE: This study aimed to assess the benefit-risk ratio by determining diagnostic yield and safety of brainstem biopsies in adult patients. The secondary objectives were (i) to compare brainstem biopsy safety and postbiopsy patients' outcomes and survival with those of patients biopsied for a brain or cerebellar lesion, and (ii) to assess the impact of brainstem biopsy on final diagnosis and further therapeutic management.
METHODS: Among 1784 stereotactic biopsies performed in adult patients at a tertiary center between April 2009 and October 2020, we retrospectively examined 50 consecutive brainstem biopsies. We compared variables regarding diagnostic yield, safety and post-biopsy outcomes between brainstem biopsy patients and brain/cerebellum biopsy patients.
RESULTS: Brainstem biopsy led to a diagnosis in 86% of patients (94.6% in patients with suspected tumor). Lesion contrast enhancement on imaging was the sole predictor of obtaining a diagnosis. Rates of symptomatic complications and mortality were significantly higher in brainstem biopsy patients compared to brain/cerebellum biopsy patients (20% vs 0%; p < 0.001 and 6% vs 0%; p = 0.01, respectively). Transfrontal trajectory and prebiopsy swallowing disorders were predictors of brainstem biopsy-related symptomatic complications. Brainstem biopsy findings led to diagnostic change in 22% of patients.
CONCLUSIONS: Stereotactic biopsy in adult patients with brainstem lesion has a high diagnostic yield. Although stereotactic brainstem biopsy is associated with more functional and fatal complications than biopsies targeting the brain/cerebellum, its safety profile appears acceptable. Thus, the benefit-risk ratio of stereotactic biopsy in patients with brainstem lesion is favorable but should nevertheless be carefully weighted on a case-by-case basis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Benefit-risk ratio; Brainstem tumor; Diagnostic yield; Outcome; Prognosis; Safety; Survival

Year:  2022        PMID: 36083426     DOI: 10.1007/s11060-022-04129-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  40 in total

1.  Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.

Authors:  Elke Pfaff; Ahmed El Damaty; Gnana Prakash Balasubramanian; Mirjam Blattner-Johnson; Barbara C Worst; Sebastian Stark; Hendrik Witt; Kristian W Pajtler; Cornelis M van Tilburg; Ruth Witt; Till Milde; Martin Jakobs; Petra Fiesel; Michael C Frühwald; Pablo Hernáiz Driever; Ulrich W Thomale; Martin U Schuhmann; Markus Metzler; Konrad Bochennek; Thorsten Simon; Matthias Dürken; Michael Karremann; Stephanie Knirsch; Martin Ebinger; André O von Bueren; Torsten Pietsch; Christel Herold-Mende; David E Reuss; Karl Kiening; Peter Lichter; Angelika Eggert; Christof M Kramm; Stefan M Pfister; David T W Jones; Heidi Bächli; Olaf Witt
Journal:  Eur J Cancer       Date:  2019-04-22       Impact factor: 9.162

2.  Pediatric intrinsic brainstem lesions: clinical, imaging, histological characterization, and predictors of survival.

Authors:  Barbara Albuquerque Morais; Davi Jorge Fontoura Solla; Hamilton Matushita; Manoel Jacobsen Teixeira; Bernardo A Monaco
Journal:  Childs Nerv Syst       Date:  2019-12-13       Impact factor: 1.475

3.  Increasing the diagnostic yield of stereotactic brain biopsy using intraoperative histological smear.

Authors:  Bertrand Mathon; Aymeric Amelot; Karima Mokhtari; Franck Bielle
Journal:  Clin Neurol Neurosurg       Date:  2019-10-03       Impact factor: 1.876

4.  Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas.

Authors:  Stephanie Puget; Kevin Beccaria; Thomas Blauwblomme; Thomas Roujeau; Syril James; Jacques Grill; Michel Zerah; Pascale Varlet; Christian Sainte-Rose
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

5.  Stereotactic biopsy for brainstem tumors in pediatric patients.

Authors:  José L Pérez-Gómez; Carlos A Rodríguez-Alvarez; Alfonso Marhx-Bracho; Fernando Rueda-Franco
Journal:  Childs Nerv Syst       Date:  2009-09-26       Impact factor: 1.475

6.  Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety.

Authors:  Bertrand Mathon; Alexandre Le Joncour; Franck Bielle; Karima Mokhtari; Anne-Laure Boch; Matthieu Peyre; Zahir Amoura; Patrice Cacoub; Nadia Younan; Sophie Demeret; Eimad Shotar; Sonia Burrel; Arnaud Fekkar; Jérôme Robert; Aymeric Amelot; Marc Pineton de Chambrun
Journal:  Eur J Intern Med       Date:  2020-07-10       Impact factor: 4.487

7.  Complications after frame-based stereotactic brain biopsy: a systematic review.

Authors:  Maximilien Riche; Aymeric Amelot; Matthieu Peyre; Laurent Capelle; Alexandre Carpentier; Bertrand Mathon
Journal:  Neurosurg Rev       Date:  2020-01-04       Impact factor: 3.042

Review 8.  Brainstem glioma: a review.

Authors:  Sean A Grimm; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

9.  Nondiagnostic CT-guided stereotactic biopsies in a series of 407 cases: influence of CT morphology and operator experience.

Authors:  A Ranjan; V Rajshekhar; T Joseph; M J Chandy; S M Chandi
Journal:  J Neurosurg       Date:  1993-12       Impact factor: 5.115

10.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.